Heron Therapeutics shares surge 20.46% intraday after strong Q4 revenue driven by ZYNRELEF’s 35% quarter-over-quarter growth.

Heron Therapeutics surged 20.46% intraday trading following the announcement of preliminary Q4 2025 net revenue results, driven by a 35% quarter-over-quarter revenue increase in its flagship product ZYNRELEF®. The company reported $40.5 million in Q4 net revenue, with ZYNRELEF contributing $12.5 million, marking the largest growth within its portfolio. CEO Craig Collard highlighted the momentum in the Acute Care franchise, particularly ZYNRELEF and APONVIE, as key drivers of the results. The product’s performance as a non-opioid post-surgical pain solution has bolstered investor confidence in Heron’s market position. Full-year 2025 net revenue reached $154.9 million, reinforcing the stock’s upward trajectory amid strong demand for its acute care offerings.